<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H1260177C6FA2465DB21A4D5BE1749CDC" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1826 IH: Prostate-Specific Antigen Screening for High-risk Insured Men Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-28</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1826</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230328">March 28, 2023</action-date><action-desc><sponsor name-id="B001275">Mr. Bucshon</sponsor> (for himself, <cosponsor name-id="C001067">Ms. Clarke of New York</cosponsor>, <cosponsor name-id="D000628">Mr. Dunn of Florida</cosponsor>, and <cosponsor name-id="C001125">Mr. Carter of Louisiana</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XXVII of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without the imposition of cost-sharing requirements, and for other purposes.</official-title></form><legis-body id="H1DE33B69152E4801BFF657727E9416EE" style="OLC"> 
<section id="H6585B176420142AF913CF83FC6C98843" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Prostate-Specific Antigen Screening for High-risk Insured Men Act</short-title></quote> or the <quote><short-title>PSA Screening for HIM Act</short-title></quote>.</text></section> <section id="H9C3E2220DEC94546A5D1EEF9544712A4"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text>
<paragraph id="H6F27DBAA257845D792554C05919AE237"><enum>(1)</enum><text display-inline="yes-display-inline">Prostate cancer is the second leading cause of cancer death in men in the United States with 1 in 41 men dying from prostate cancer and more than 34,700 men estimated to die from prostate cancer in 2023.</text></paragraph> <paragraph id="HDCF7770C1490447F94844B37782FD097"><enum>(2)</enum><text display-inline="yes-display-inline">Prostate cancer is the second most commonly diagnosed cancer in the Nation with 1 in 8 men being diagnosed in their lifetimes, 3.1 million men in the United States living with a diagnosis, and over 288,000 men estimated to be diagnosed in 2023.</text></paragraph>
<paragraph id="HBBA4797B4B0A4283893E90A2356D730D"><enum>(3)</enum><text>The survival rate for prostate cancer diagnosed in early stage is near 100 percent but prostate cancer diagnosed in late stage has only a 30-percent survival rate.</text></paragraph> <paragraph id="H00B5A87D025F4A8AA30CA10525487CC7"><enum>(4)</enum><text>There are few, if any, symptoms of prostate cancer before it reaches late stage.</text></paragraph>
<paragraph id="H55A67214185E4BB4B36FB1C4CFA83A3E"><enum>(5)</enum><text>African-American men have a disproportionately higher rate of prostate cancer and are 70 percent more likely to be diagnosed with prostate cancer than White men, with 1 in 6 African-American men developing prostate cancer in their lifetimes.</text></paragraph> <paragraph id="HFEAB056D424D4F2981A22C731EECBD63"><enum>(6)</enum><text>African-American men are 2.1 times more likely to die from prostate cancer than White men.</text></paragraph>
<paragraph id="H534E15ECC49A450798F2F1FF416C46F4"><enum>(7)</enum><text>Men with a father or brother with prostate cancer are more than twice as likely to be diagnosed with prostate cancer than men without a family history.</text></paragraph> <paragraph id="HAC69F994673045488F5637C6B20847EB"><enum>(8)</enum><text>The common clinical definition for men at high-risk of prostate cancer includes African-American men and men with a family history.</text></paragraph>
<paragraph id="HF87FA4E229DA4FB0B0D0243E1AE7AD71"><enum>(9)</enum><text>Most of the major cancer and urological societies recommend beginning screening discussions earlier for African-American men and those with a family history of prostate cancer.</text></paragraph> <paragraph id="H808BA663E4284501954A3A7F4718A1A8"><enum>(10)</enum><text>The United States Preventive Services Task Force has encouraged research on screening African-American men, including whether to screen African-American men at younger ages, and has identified this research as a high-priority cancer research gap.</text></paragraph>
<paragraph id="H81B6B3A9753C4F8E84E5C5280E617235"><enum>(11)</enum><text>Barriers to screening should be minimized for high-risk men in order to catch asymptomatic prostate cancer before it metastasizes and the survival rate is dramatically reduced.</text></paragraph> <paragraph id="H2CB865870B4340ECB10CEDF0ED8ECBB5"><enum>(12)</enum><text>The cost of treating metastatic prostate cancer in the United States health care system is hundreds of millions of dollars more annually than the cost of treating localized, early-stage cancer.</text></paragraph></section>
<section id="HA4EA0F2CB4434823A333F43CB37865D8"><enum>3.</enum><header>Requirement for group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for prostate cancer screenings without imposition of cost-sharing requirements</header>
<subsection id="HA46AAC3CE5B845C3BCD9542B27075A20"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Subsection (a) of section 2713 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-13">42 U.S.C. 300gg–13</external-xref>) is amended to read as follows:</text> <quoted-block display-inline="no-display-inline" id="H37259813DD034B3C82C7EA3349175068" style="OLC"> <subsection id="HBD95B423AF284BC192407E665BF3FAAD"><enum>(a)</enum><header>Coverage of preventive health services</header> <paragraph id="H685D943CCF07403C88FA6F958CC7AE81"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">A group health plan and a health insurance issuer offering group or individual health insurance coverage shall, at a minimum, provide coverage for and shall not impose any cost-sharing requirements for—</text>
<subparagraph id="HBD028A6AF7344827B746DC2CEBCD47F3"><enum>(A)</enum><text>evidence-based items or services that have in effect a rating of <quote>A</quote> or <quote>B</quote> in the current recommendations of the United States Preventive Services Task Force;</text></subparagraph> <subparagraph id="H3261386E6F114E37949226A895539B82"><enum>(B)</enum><text display-inline="yes-display-inline">immunizations that have in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention with respect to the individual involved;</text></subparagraph>
<subparagraph id="H68A237FD3B044639B5C5F96D9C2001F6"><enum>(C)</enum><text display-inline="yes-display-inline">with respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided for in the comprehensive guidelines supported by the Health Resources and Services Administration;</text></subparagraph> <subparagraph id="H959A4950DFB34DF4B4D73A7263A36BAD"><enum>(D)</enum><text>with respect to women, such additional preventive care and screenings not described in subparagraph (A) as provided for in comprehensive guidelines supported by the Health Resources and Services Administration for purposes of this subparagraph; and</text></subparagraph>
<subparagraph commented="no" id="HF74ED6D16E33442185342BC54AB87026"><enum>(E)</enum><text display-inline="yes-display-inline">with respect to men who are age 40 and over and are at high risk of developing prostate cancer (including African-American men and men with a family history of prostate cancer (as defined in paragraph (2))), such additional evidence-based preventive care and screenings not described in subparagraph (A) for prostate cancer.</text></subparagraph></paragraph> <paragraph id="HB38A1DDB195C4749AC03884E18511FB5"><enum>(2)</enum><header>Men with a family history of prostate cancer defined</header><text>For purposes of paragraph (1)(E), the term <term>men with a family history of prostate cancer</term> means men who have a first-degree relative—</text>
<subparagraph id="H5CEAC8CFD0D64B87BEB48946F05D9A45"><enum>(A)</enum><text display-inline="yes-display-inline">who was diagnosed with prostate cancer;</text></subparagraph> <subparagraph id="H28E1419558574D6483E6B94F30DF9536"><enum>(B)</enum><text>who developed prostate cancer;</text></subparagraph>
<subparagraph id="H160A3AEAA1B34012A1EF5A8FE75263D7"><enum>(C)</enum><text>whose death was a result of prostate cancer;</text></subparagraph> <subparagraph id="H26E83C9DFF15473F9B4F476C7F70E2C0"><enum>(D)</enum><text display-inline="yes-display-inline">who have been diagnosed with a cancer known to be associated with increased risk of prostate cancer; or</text></subparagraph>
<subparagraph id="HDACFE316CD544B69AC6E088F60071795"><enum>(E)</enum><text display-inline="yes-display-inline">who has a genetic alteration known to be associated with increased risk of prostate cancer.</text></subparagraph></paragraph> <paragraph id="H4BFDEB3B97A44820A0A99DE2B909F785"><enum>(3)</enum><header>Clarification regarding breast cancer screening, mammography, and prevention recommendations</header><text>For the purposes of this Act, and for the purposes of any other provision of law, the current recommendations of the United States Preventive Service Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current other than those issued in or around November 2009.</text></paragraph>
<paragraph id="HAD404FA003F84D64BD90F547F0D065D8"><enum>(4)</enum><header>Rule of construction</header><text>Nothing in this subsection shall be construed to prohibit a plan or issuer from providing coverage for services in addition to those recommended by the United States Preventive Services Task Force or to deny coverage for services that are not recommended by such Task Force.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="HA680E691C14D4A948C0C90AA64D9D9D2"><enum>(b)</enum><header>Effective date</header><text>The amendment made by subsection (a) shall apply with respect to plan years beginning on or after January 1, 2024.</text></subsection></section> 
</legis-body></bill>

